AGI to solve disease

A deep-tech start-up incubated and co-developed by the UK Golden Triangle universities (Oxford, Cambridge, and King’s College London) that applies Artificial General Intelligence (causal predictive & generative AI) based on symbolic regression and program synthesis to deliver decentralised mission-driven solutions to everyone today.

Hybrid AGI enables scalable predictive Intelligence-as-a-Service

OIA’s vision is a world where Superintelligence is used first and foremost for meaningful purposes. For OIA and world experts in logic and computability, AGI is about ultimate optimal prediction and less about simulating human behaviour, as with chatbots or domestic tasks chore robots.

Superintelligence was solved by mathematicians (Kolmogorov, Chaitin, and Solomonoff) in the late 1950s in the same workshop at Dartmouth in the U.S. where the term AI was coined and the field started. This type of causal and optimal inference type of AGI is a generalisation of all other AIs, including Generative AI and human intelligence. However, it was hard to exploit until recently because of the computational resources required, recalling the difficulties that neural networks once faced.

OIA’s founder, whose Ph.D. thesis advisor was one of those mentioned above who solved AGI, is the world leader in the implementation and validation of this generalisation of AGI that has found applications in areas ranging from cell and molecular biology to business intelligence, for which the company has won several prestigious grants and prizes in the US, UK, Sweden, and the UAE.

With more than 100 peer-reviewed papers in some of the most prestigious scientific journals, OIA’s AGI inference engine, is meant to help with the most pressing challenges of the human condition, from antibiotic resistance to chronic inflammation to cancer.

Developed by OIA, Algocyte® is a suite of AGI-driven solutions that enable remote and personal digital endpoints in healthcare pathways from clinic to home and to understand health and disease, find prescription gaps and enable home-driven precision healthcare and predictive medicine.

With two medical device patents granted in the U.S., OIA’s Algocyte® combines biochemistry technology, biomedical imaging, mechatronics, and nanotechnology with AI to learn and build biological digital twins based on users’ personal and longitudinal data for remote digital care. A detailed version of the individual’s health current baseline against which to track deviations and test hypotheses for differential prediction—an early detection system based upon our AGI inference engine towards extend a person’s life and health span.

23m+

Access to

enriched patient longitudinal records

250K

proprietary

super accurate labelled repository of normal and pathological single-cell images for AI training purposes

100+

published

peer-reviewed papers
validating OIA’s science

Access to

120m+

diagnosis & clinical data points

1tn+

proprietary

mechanistic, explainable, and interpretable computable models and testable scientific hypotheses

won

multiple

innovation & AI prizes beating companies such as Microsoft, Accenture, and Etihad in international competitions

Fully sponsored and produced by the highest-impact scientific journal, Nature, this video, based on our peer-reviewed publication in the same journal,  explains OIA’s causal and model-driven approach to Artificial General Intelligence.

Algocyte’s universal input devices

  • We aim to place a fully automated portable lab in every home to monitor people’s health from anaemia to infection to cancer to auto immune diseases

  • Data collection: Capable of ingesting multiple data streams from multiple types of data-generating and testing IoT devices

  • Collects & deals with multiple sources of data, including multi omics (genetics, metabolomics, transcriptomics, lipidomics and proteomics)

  • An open platform on which commercial & academic solutions can be developed and deployed by software and reagent updates

  • Automation tools for classification and triaging

  • Can enable detection of early signals for better and faster responses

  • Can monitor & learn from users over time

  • Advanced AI-reasoning & predictive capabilities

  • Can provide links to specialised guidance

Generative AGI diagnostics

Leading AI-driven solutions built using symbolic regressive and predictive Artificial General Intelligence are causal model-driven.

OIA’s Proprietary technology is based on years of research at Oxford, Cambridge, King’s College London, and the Karolinska Institute, which awards the Nobel Prize in Physiology or Medicine.

Built on 3 key pillars

Algocyte® is an AGI precision diagnostics platform providing proprietary quantitative risk assessment scores

Quantitative Precision

Prediction, Prevention and Early Detection

Professionals can analyse users’ results relative to personalised norms, triage, and flag concerning trends

Individualised Learning and Monitoring

The Algocyte® platform learns from each user based on a digital twin baseline and builds their personal profile allowing forecasting, prediction or diagnosing

Want to find out more?

In our downloadable PDF, we share the in-depth science behind our breakthrough product. Delve into the specifics of our leading precision & predictive platform.